Dr. Mark has been the senior pulmonary pathologist since his initial appointment at the Massachusetts General Hospital. Dr. Mark is the director of the autopsy service, which performs approximately three hundred-fifty cases annually. He is a District Medical Examiner for the Commonwealth of Massachusetts. Dr. Mark is an Associate Professor of Pathology at Harvard Medical School and in the, Division of Health Sciences and Technology at Massachusetts Institute of Technology. Dr. Mark hails from Ohio and attended Oberlin College, Oberlin, Ohio. He graduated from Harvard Medical School, having done a post-sophomore research fellowship during medical school in Switzerland. He did his internship in internal medicine at Stanford University Medical Center, Palo Alto, California. He trained in anatomic and clinical pathology at the Massachusetts General Hospital and is board certified in pathological anatomy and clinical pathology. He has also functioned as a dermatopathologist at the Massachusetts General Hospital and is board certified in dermatopathology. He has authored many articles and Case Records of the Massachusetts General Hospital, principally in the field of pulmonary pathology. He is the single author of the book “Lung Biopsy Interpretation.” He has given post-graduate courses for the International Academy of Pathology, the American Society of Clinical Pathologists, and the American College of Chest Physicians. He has been an invited professor or lecturer in twenty countries on four continents and in twenty-four states and provinces in the United States and Canada. Dr. Mark served two years of active duty in the United States Army Medical Corps at the U. S. Army Reference Laboratory in Landstuhl, Germany.

Dr. Mark has a special interest in diseases of the pleura including malignant mesotheliomas, carcinomas including atypical carcinoids, vasculitis including Wegener’s granulomatosis, infectious diseases including tuberculosis, congenital lung disease, interstitial lung disease, and dust diseases.

PubMed

Dr. Nickeleit is a Privatdozent at the University of Basel, Switzerland and a tenured Professor of Pathology and Laboratory Medicine, adjunct Professor of Medicine, Director of the Division of Nephropathology and Director of the Renal Pathology Fellowship Training Program at The University of North Carolina School of Medicine at Chapel Hill. He received his medical doctorate degree from Christian-Albrechts University, Kiel, Germany. Dr Nickeleit started his residency training in anatomic pathology at the University of Basel, Switzerland, continued with research training at Stanford University Medical School, Palo Alto and completed training in anatomic pathology including fellowship training in kidney and transplant pathology at the Massachusetts General Hospital/Harvard Medical School in Boston. He subsequently worked as a pathologist in Graz, Austria and Basel, Switzerland where he received the “venia legendi” and habilitation in general and special pathology. He joined UNC at Chapel Hill over a decade ago. Dr Nickeleit is a renowned kidney and transplant pathologist with a long track record of publications and invited lectures. He has been recognized as one of the “Best Doctors in America” for several years and currently serves on the editorial board of 8 journals. He was elected councilor of ‘The Renal Pathology Society’ in 2009, served as RPS president in 2013 and currently steers two ‘Banff-Working Groups’ on transplant pathology.

Dr Nickeleit’s scholarly activities focus on rejection induced changes in renal allografts and on polyomavirus nephropathies. In collaboration with Dr. Singh from UNC he characterized the first highly accurate non-invasive biomarker for the diagnosis of polyomavirus nephropathy, i.e. the urinary “Polyomavirus-Haufen Test”.

PubMed

Dr. Huan-You Wang is a Professor of Pathology in the Department of Pathology, University of California San Diego (UCSD), USA. He is also Director of Hematopathology Fellowship Program at UCSD. Dr. Wang got his MD degree from China and his PhD degree from UCSD in 2000. He did his residency training in Surgical Pathology and Clinical Pathology at University of Virginia from 2000-2004. Dr. Wang completed his Hematopathology Fellowship at University of Pennsylvania from 2004-2005. He served as Assistant Professor of Pathology at University of Texas Southwestern Medical Center at Dallas from 2005-2009. He returned back to UCSD as Associate professor in 2009 and was promoted to full professor in 2013. He has published 62 peer-reviewed research articles in top bio-medical journals. There are total of 1089 citations of published papers with total impact factors of 336 as of Dec 8, 2015.

Dr. Huan-You Wang’s clinical and research interests and expertise are in the realm of hematolymphoid disorders in particular lymphomas and leukemias. Dr. Wang has expertise in cytomorphology, flow cytometry, genetics and molecular genetics, as well as diagnostic molecular pathology including next generation sequence (NGS).

PubMed

Dr. Judy Ann King is a professor and Director of Anatomic Pathology at LSU Health Shreveport, Shreveport, LA. She received her Ph.D. in Anatomy from Quillen-Dishner College of Medicine (ETSU) and M.D. from the Medical University of South Carolina. After an internship in Internal Medicine, she completed her residency in Pathology at the University of South Alabama. She is Medical Director of parts of the lab. Her clinical area of focus is Anatomic Pathology, including renal biopsy interpretation. She runs the WVU Electron Microscopy Core Facility which provides expertise in electron microscopy for researchers. She has published over 126 abstracts and presentations and 76 research articles.

Dr. Judy Ann King research interests include utilization of electron microscopy techniques to assess human disease and analysis of ultrastructural changes for research applications (including interactions of tumor cells with other cells).

PubMed

Dr. Jianhua Luo is currently a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh, USA. He earned a doctoral degree from the University of Maryland at Baltimore in Pharmacology in 1992. He did his MD in Medicine from the Guangzhou Medical Institute, Canton, China in 1982. He was a Research Assistant Professor (1999-2000), Assistant Professor (in the tenure-stream) (2000-2005) and Associate Professor (2005-2012) in Department of Pathology, University of Pittsburgh. Dr. Luo has been studying molecular pathology related to human malignancies in the last 23 years. He has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. He published morethan 93 peer reviewed papers and book chapters; serves as an editorial board member and reviewer on several research journals.

Dr. Jianhua Luo’s research interests involve identifying new tumor suppressor genes, oncogenes and tumor markers in prostate cancer and hepatocellular carcinoma using high throughput and comprehensive analyses. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, and AR-MCM7 oncogenic pathway. As the Director of High Throughput Genome Center, he has collaborated extensively with faculty members in the UPMC and University campuses to use high throughput genome sequencing and high throughput microarray analyses to develop tests for molecular pathology and to investigate novel mechanisms for signal transduction and identifying markers for human diseases.

PubMed

Dr. Thomas J. Lawton is currently Professor of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill. Dr. Lawton is a board-certified surgical pathologist with 20 years of post-fellowship experience in academia and the private sector. A graduate of the University of Michigan Medical School, Dr. Lawton completed his residency and fellowship training at the University of Pennsylvania and Stanford University. He has served on the medical school faculties at the University of Pennsylvania, the University of Washington. Dr. Lawton has co-authored numerous journal articles and textbook chapters on breast pathology including being the principle author and editor of Cambridge University Press' “Breast (Illustrated Surgical Pathology Series”) and is co-author of the textbook “Breast Imaging and Pathologic Correlations: A Pattern-Based Approach” with his Radiology colleague from Harvard Medical School. He has lectured nationally and internationally on breast pathology and has been Co-Director of two Short Courses on breast pathology at the USCAP. He recently served as Presiding Officer for the Radiology/Pathology Intervention Program at the 100th Annual meeting of RSNA where he was a keynote speaker on high risk lesions of the breast.

Dr. Thomas J. Lawton has two main areas of clinical research: Dr. Lawton’s first main area of research interest is in markers of breast cancer risk and the study of specific molecular alterations related to breast cancer prediction, prognosis and treatment. He has served as a pathologist consultant and co-investigator on numerous multi-disciplinary breast cancer research grants dealing with prediction and prognosis, and he was one of several pathologists involved in evaluating and validating a now commercially available test for risk stratification in ER-positive breast cancers. Dr. Lawton’s second main area of research interest is in high risk (non- cancerous) lesions of the breast with a particular interest in the role of core needle biopsy in evaluating high risk patients. He has published and spoken extensively on this topic with a Radiology colleague of mine at Brigham and Women’s Hospital. Of the high risk lesions, lobular neoplasia has become a major focus of mine with particular emphasis on the role of lobular neoplasia as a precursor lesion akin to ductal carcinoma in situ.

PubMed

Dr. Nan-Haw Chow is a tenured Professor of Pathology at the National Cheng Kung University, Taiwan. He received his M.D. from China Medical University, Taichung and trained in pathology at the National Taiwan University. Dr. Chow has been practicing since 1989 at the National Cheng Kung University Hospital. From then on, Chow was dedicated to urinary tract cancer research and his interests also include tumor biology, molecular pathology, and quality assurance. He has published 137 articles and was the lead editor of the Urothelial Carcinoma special issue in the Advances in Urology. Currently, Chow is editorial board member of 8 clinical journals and has been invited as a reviewer for prestigious medical journals. Chow is also an adjunct professor of the Institute of Molecular Medicine, National Cheng Kung University.

Dr. Nan-Haw Chow research interest includes Genitourinary pathology, tumor biology, molecular mechanisms of carcinogenesis, tumor marker, molecular pathology, gastrointestinal pathology.

PubMed

Dr. Tawfik is currently the Director of Anatomical and Surgical Pathology and a Professor of Pathology at KUMC. Dr Tawfik received his Doctorate of Medicine from the Faculty of Medicine at Cairo University, Egypt and his PhD in Pathology from Kansas University Medical Center (KUMC). He completed his Pathology residency training at KUMC. He is certified by the American Board of Pathology in Anatomic and Clinical Pathology and Cytopathology. Dr Tawfik provides clinical services in Surgical Pathology and Cytopathology with special expertise in gynecologic, breast and lung pathology. His research program has focused on Tumor Biomarkers, Breast and GYN Pathology, Digital Pathology, Image Analysis, Reproductive Immunology, Endometriosis and Atherosclerosis. He has authored over 180 research publications published in eminent peer-reviewed journals and has written and edited several Pathology textbooks. He serves on the Editorial Board of several leading pathology journals. He is frequently sought out to provide his expertise at medical conferences and academic institutions and is a member of several medical groups and associations.

Dr. Tawfik research includes Surgical Pathology, Cytopathology, Immunohistochemistry, Image Analysis, Telepathology, Tumor Biology, Translational Research.

PubMed

Dr. Ren-Ke Li is a Professor of Surgery and Laboratory Medicine and Pathobiology at the University of Toronto and a Senior Scientist at the Toronto General Research Institute. He earned his PhD in Clinical Biochemistry, Biochemistry from the University of Toronto, Toronto, Canada (1988-1992). He completed his MSc in Clinical Biochemistry from the University of Toronto, Canada (1987-1988). Dr. Ren-Ke Li did his Post-Doctoral Fellow in Cardiovascular Surgery from the University of Toronto (1992-1993). Dr. Li has published 209 peer-reviewed papers in his field of research.

Ren-Ke Li research focuses on the development of novel therapies for repairing and regenerating the injured myocardium and improving cardiac function after a myocardial infarction (MI), Cell transplantation to restore heart function after injury , Identification of the mechanisms responsible for the beneficial effects of cell therapy, Evaluation of the safety and efficacy of cell therapy for clinical applications, Identification of aging as a major limitation of the clinical results of cell therapy, Rejuvenation, a new concept in stem cell therapy for aged patients, Development of a platform for non-invasive, repetitive, targeted and double-targeted gene delivery for cardiac regeneration and cell therapy.

PubMed

Dr. Asif Rashid is currently a tenured professor of pathology and section chief of Gastrointestinal and Liver Pathology at the University of Texas MD Anderson Cancer Center. He is a gastrointestinal and liver pathologist and molecular biologist by training. He earned a doctoral degree from the Boston University School of Medicine in Molecular Immunology in 1991. He did residency in Anatomic Pathology and fellowship in Surgical Pathology at the Massachusetts General Hospital and Harvard University; and Gastrointestinal and Liver Pathology fellowship at The Johns Hopkins Hospital and University. He was a faculty in Pathology and Oncology at The Johns Hopkins University before moving to the University of Texas MD Anderson Cancer Center in1999. He has published more than 200 articles in scientific generals, has written several book chapters and has given many invited talks and scientific presentations.

Dr.Asif Rashid research interest includes Gastrointestinal pathology,Genetic epidemiology of K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers; Genetic alterations in hepatocellular carcinomas; Phenotypic and molecular characteristics of hyperplastic polyposis; CpG island methylation in colorectal adenomas; β -catenin mutations in biliary tract cancers.

PubMed

Dr. Jun Qin Mo is a Professor of Pathology in the Department of Pathology, University of California San Diego (UCSD), USA. Dr. Mo received her MD degree from China. She had her residency training in Anatomic Pathology and Clinical Pathology at Harbor-UCLA, Los Angeles and University of Cincinnati, Ohio. Dr. Mo did her pediatric fellowship at Cincinnati Children Hospital Medical Center (CCHMC) from 2002-2004, and then she stayed on as faculty there for the next 10 years. Over two years ago, Dr. Mo joined Rady Children Hospital and served as a full professor in UCSD. Her clinical areas of focus are pediatric surgical pathology and pediatric hematopathology. In addition to her clinical services, Dr. Mo has been actively involved in teaching and research. She has published over 54 peer-reviewed research articles.

Dr. Jun Qin Mo research interests includes- Hemophagocytic lymphohistiocytosis; Pediatric hematologic malignancy; Pediatric vascular disease.

PubMed

Dr. Lawrence Zukerberg is Associate Professor of Pathology and Associate Pathologist, Department of Pathology, Massachusetts General Hospital. Dr. Lawrence Zukerberg graduated with a B.A. degree from the Princeton University in 1982. He obtained his M.D. from UMDNJ - Rutgers Robert Wood Johnson Medical School, Piscataway in 1986. He has expertise in gastrointestinal, hematological, and frozen section pathology. He is the Principal Investigator with a research program focused on studying the biology and biochemistry of a novel gene, Cables that interacts with cell cycle control proteins including, CDK2, p53, beta-catenin, mTOR and is a novel cell cycle regulator and tumor suppressor gene. Cables expression is lost in many primary human cancer and it loss can prolong the life of stem cells in some mouse organs. He has published more than 120 research articles.

Dr. Lawrence Zukerberg areas of expertise include gastrointestinal, hematological, and frozen section pathology. Some of the research projects of Dr. Zukerberg include studying the relationship of Cables to cell cycle control proteins, generating and studying Cables mutant mice, and determining the pathways involved in Cables cell growth regulation. Other recent projects have included identification of cyclin D1 as a marker of mantle cell lymphoma and understanding specific reactive conditions that mimic lymphoma.

PubMed

Dr. Rossitza Lazova is an Associate Professor of Dermatology and Pathology, Yale University School of Medicine. Dr. Lazova graduated from Sofia Medical University, Sofia, Bulgaria, trained in Clinical Pathology in Bulgaria, immigrated to the United States, and completed a residency in Anatomic and Clinical Pathology at the University of Rochester Medical Center in Rochester, New York. She trained in Dermatopathology with Dr. A. Bernard Ackerman at the Institute for Dermatopathology at Thomas Jefferson Medical College in Philadelphia. After the completion of her fellowship Dr. Lazova started her academic career as an Assistant Professor at the Department of Dermatology, Yale University School of Medicine in 1997. She has been a Director of the Dermatopathology Fellowship at Yale University for more than eleven years. Dr. Lazova has trained many fellows and residents. She has developed an international program and has supervised and taught over forty-five physicians from four continents over a 13-year period. Recently, she introduced Imaging Mass Spectrometry as a method to be used in the diagnostic process of difficult melanocytic lesions. Dr. Lazova has published numerous articles in peer – reviewed journals and is a co – author of two textbooks: Differential Diagnosis in Dermatopathology II, second edition, and Atlas of Practical Mohs Histopathology. She is on the editorial board of several scientific journals, and has served in several professional societies. She is currently the Vice President of the International Society of Dermatopathology.

Dr. Lazova’s main interests are in Spitz nevi, Spitzoid melanomas and atypical Spitzoid neoplasms; melanocytic nevi on special anatomic sites; malignant melanoma and melanoma in children.

PubMed

Dr. Evgeny Yakirevich is Associate Professor of Pathology and Laboratory Medicine at the Warren Alpert Medical School of Brown University, in Providence, RI, and Staff Pathologist at Lifespan Academic Medical Center. He is also Director of Surgical Pathology Fellowship Program at Brown University, Director of Lifespan Tissue Bank, and Co-Director of Molecular Pathology Core at Rhode Island Hospital. Dr. Yakirevich received his M.D. in 1987 from Vitebsk State Medical University in Belarus, and his D.Sc. in immunology and molecular biology in 1997 from Technion-Israel Institute of Technology in Haifa. He completed residency in surgical pathology at Carmel Medical Center in Haifa, Israel, and residency in anatomic and clinical pathology at Brown University, Providence, RI, and is board-certified in anatomic and clinical (AP/CP) pathology. He completed his training in gastriontestinal Pathology at Brown University. His professional and research expertise is in the areas of genitourinary, breast, gastrointestinal, and liver pathology.

Dr. Yakirevich clinical and research expertise includes tumors of the kidney, breast, gastrointestinal, and pancraetobiliary system. His research interests are in the relationships between molecular markers, including genomic alterations, RNA expression profiles, and protein markers, and the clinical phenotype and long-term outcomes in cancer.

PubMed

Dr. Pauline M. Chou is a professor in the Department of Pathology Northwestern University’s Feinberg School of Medicine. She is also head of anatomic pathology Ann and Robert H. Lurie Children’s Hospital of Chicago. She completed her graduation in medicine from the Institute of Medicine, Mandalay, Burma (1976). Dr. Pauline did her fellowship in Pediatric Pathology in the Department of Pathology, Children's Memorial Hospital (1987-1989). She started her career in pediatric pathology under the mentorship of Dr. Frank Gonzalex-Crussi. As program director and head of Anatomic pathology for years, she have been able to work with her trainees and colleagues describing and working on the remarkable differences between pediatric and adult tumors. She has published 121 research articles and 5 book chapters and a book entitled “Pediatric Cytopathology and Histopathologic correlation".

Dr. Pauline M. Chou research Interest includes Pediatric tumors, Sarcomas and soft tissue tumors, Fine needle aspirations and histologic correlation, Quality assurance in anatomic pathology.

PubMed

Dr. Chang is a professor in the Department of Laboratory Hematology Toronto General Hospital, Canada. He received his MD from Jiangxi Medical University in China, M.Sc. and PhD from the Institute of Medical Science, University of Toronto, Canada. He then trained and specialized in Hematological Pathology and joined the faculty as a staff physician at the Toronto General Hospital/University Health Network in 1998 and worked as the Director of Clinical Flow Cytometry/Laboratory Hematology in 2000. His research has mainly dealt with the characterization of genetic events for initiation and progression of multiple myeloma (MM) as well as identification of prognostic factors and therapeutic targets in MM. Dr. Chang serves on the editorial board of several scientific journals and has published over 120 peer-reviewed papers, over 80% of those being as a senior or principal author. Dr. Chang received many research and teaching awards including the Leukemia and Lymphoma Society Scholar Award, the TransAmerica Life Canada Award, and the 2015 Faculty of Medicine Excellence in Life Sciences Teaching Award at University of Toronto.

Dr. Hong Chang research interests are Identification of molecular genetic aberrations in the initiation and progression of multiple myeloma (MM) and contribution to the genetic based risk stratification of MM, Preclinical study of novel therapeutic agents including p53 activating small molecules and microRNAs in MM, Evaluation of molecular and immunophenotypic markers in diagnosis and prognosis of acute myeloid (AML) and acute lymphoblastic leukemia (ALL).

PubMed

Dr. Yan Peng is a Professor in the Department of Pathology at the University of Texas Southwestern Medical Center at Dallas. She got her MD degree (1986) and Ph.D (1991) in Renal Physiology  from Beijing University School of Medicine. She completed her Pediatric Residency/Chief Resident at Beijing University Hospital and practiced there as a Pediatric Nephrologist till 1993. Dr. Yan Peng did her Residency training in Anatomic and Clinical Pathology from the University of Pittsburgh Medical Center (1999-2003). She took two one-year ACGME accredited fellowship trainings in Breast and Gynecologic Surgical Pathology at UPMC and Cytopathology at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston. Dr. Yan Peng has been the Director for a CLIA certified Diagnostic Immunohistochemistry Laboratory for more than 9 years. She has published more than 60 peer-reviewed scientific articles.

Dr. Peng's clinical expertise and research interest includes Breast and Gynecologic Cancer Pathology, Cytopathology, and Diagnostic Immunohistochemistry with a particular interest in diagnostic, prognostic and predictive tumor biomarkers in human cancers.

PubMed

Dr. Ellen C. Riemer is an associate professor in the Department of Pathology and Laboratory Medicine at the Medical University of South Carolina, in Charleston, SC. She received an A.B. from Bryn Mawr College, a J.D. from the University of Wisconsin-Madison, and received her M.D. in 1997 from Tel Aviv University Sackler School of Medicine. Dr. Riemer completed her a residency in pathology at the New York Presbyterian Hospital, Columbia Presbyterian Medical Center of the College of Physcians and Surgeons of Columbia University. This was followed by a fellowship in Forensic Pathology at the University of Maryland, Office of the Chief Medical Examiner of the State of Maryland, and a fellowship in Pulmonary and Cardiovascular Pathology at the Johns Hopkins University School of Medicine in Baltimore, MD. Her professional expertise is in the areas of forensic pathology, pulmonary pathology and cardiovascular pathology.

Dr. Ellen C. Riemer research interests includes Forensic pathology ,Pulmonary Pathology ,Interstitial lung Disease ,Lung Transplantation,Cardiovascular Pathology.

PubMed

Dr. Brodsky Sergey is an Associate Professor in the Department of Pathology, The Ohio State University Wexner Medical Center (OSUWMC). He got his PhD from North Ossetian State Medical Academy (1992-1995). He did his fellowship in Renal and Transplant Pathology from The Ohio State University (2008-2009). Dr. Brodsky has published 90 peer-reviewed scientific articles, two book chapters. He got many honors and awards.

Dr. Brodsky Sergey research interest includes Endothelial cell dysfunction, Cellular microparticles, Angiogenesis, Intravital microscopy,Systemic and renal hemodynamics.

PubMed

Dr. Marzenna Wiranowska is associate professor at the Department Pathology and Cell Biology, Morsani College of Medicine at the University South Florida, and a member of the Moffitt Cancer Center and Research Institute Program. She obtained MS in Immunology/Microbiology from the Warsaw University and the Medical Academy of Warsaw, Poland, and continued her training in the Department of Viral Oncology, Institute de Recherches Scientifique sur le Cancer in Villejuif (Paris), France. She worked on her Ph.D. dissertation at the Memorial Sloan-Kettering Cancer Center in New York, N.Y. and obtained her Ph.D in Virology/Immunology from the Polish Academy of Sciences, Institute of Immunology and Experimental Therapy in Wroclaw, Poland. She teaches Medical (year I, II, IV), Masters in Medical Sciences Pre-Professional Program, Ph.D Graduate students, serves on the Ph.D. Graduate Committees. She was invited participant in a WHO International Collaborative Study to develop international standards for human interferon-alpha (WHO Report). She published about 60 peer reviewed papers and book chapters; serves as an editorial board member and reviewer on several research journals. Her main research area is glioma and she was invited as the editor and contributor of a book entitled “Gliomas: Symptoms, Diagnosis and Treatment Options” (2013), Nova Science Publishers.

Dr. Wiranowska conducts research in the area of brain tumor (glioma) biology, treatments and nano drug delivery systems in collaboration with the Department of Mathematical Oncology, H. Lee Moffitt Cancer Center and the USF College of Engineering. Dr. Wiranowska’s specific areas of research include: 1) studies of the extracellular matrix in the brain and its role in glioma invasion; 2) evaluation of the cellular entry and cellular localization of chlorotoxin, a scorpion derived 36 amino acid peptide designated as TM601 in glioma and other tumor cells.(TM601 was tested in Phase II clinical trials in adult recurrent glioma and in Phase I in various other tumors);and 3) evaluation of thermo-responsive double packaged system for localized delivery of therapeutics to glioma and other tumors such as ovarian carcinoma.

PubMed

Dr. Jiang Wang is an associate professor in the Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine. He received his Ph.D. from the Department of Pathology, Henan Medical University, Zhengzhou, Henan, China (1991). Dr. Jiang completed his MS from the Department of Pathology, Henan Medical University, Zhengzhou, Henan, China (1988-1991). He was a Chief Resident in the Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio (2006-2007). As a senior pathologist, he practices general pathology, cytopathology and autopsy. He has expertise in gastrointestinal/liver pathology, lung and transplant pathology. In addition to pathology daily diagnosis, Dr.Jiang Wang has been actively involved in teaching in medical students and residents,and medical research for more than 20 years. He has published more than 60 peer-reviewed papers and presented 57 abstracts in national/international conferences.

Dr. Jiang Wang research interest includes Surgical pathology, GI/ Liver pathology, Transplant pathology, Cytopathology.

PubMed

Dr. Rina Kansal is currently an Associate Professor of Pathology at the Penn State Milton S. Hershey Medical Center and serve as the Medical Director in Diagnostic Molecular Laboratory in the Department of Pathology and Laboratory Medicine. She was graduated in medicine from Maulana Azad Medical College from the University of Delhi and practiced internal medicine in New Delhi and the United Kingdom, followed by pathology training in the USA from the State University of New York at Buffalo. She completed her fellowship in oncologic pathology at Roswell Park Cancer Institute and fellowship in hematopathology from the University of Michigan and Molecular Genetic Pathology from the University of California at Los Angeles, Los Angeles, CA. She is a board-certified in Hematopathology, Molecular Genetic Pathology, Anatomic Pathology and Clinical Pathology. She has published many research papers.

Dr. Rina Kansal research interests include primarily hematopoietic neoplasms (myeloid neoplasms and lymphomas) and the application of genomic techniques for studying cancer.

PubMed

Dr. Ken He Young is an Associate Professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. He obtained his MD in medicine from the Zhejiang University School of Medicine, Zhejiang, China. His PhD from University of Lund School of Medicine, Malmo, Sweden, in Department of Pathology and Laboratory Medicine. Dr. Ken He Young has got many honors and awards some are IRG Award, 2nd, The University of Texas MD Anderson Cancer Center, 2014-2015, Myeloma SPORE 2nd DRP Award, The University of Texas MD Anderson Cancer Center, 2014-2015.

Dr. Ken H. Young research interest includes several types of hematologic malignancies, with special emphasis on pathogenesis of malignant lymphomas, especially diffuse large B-cell lymphoma (DLBCL). The goal of his team is to explore and identify genetic and non-genetic biomarkers, including p53, Myc, pTEN, Mdm2, Arf, Bcl-2, Bcl-6 genes, alone or in combination with other abnormalities in DLBCL, that predict cancer prognosis and susceptibility. Dr.Ken H.Young primary study of genomic alterations is on TP53 tumor suppressor pathway and secondary focus is on Myc oncogene.

PubMed

Dr. Xu zeng is Associate Professor in the Department of Pathology and Laboratory Medicine from Temple University Hospital, Philadelphia, Pennsylvania. Currently he is a Director of Electron microscopy, Temple University Hospital. He earned his PhD in Pharmacology from the Medical College of Ohio, Toledo, Ohio, U.S.A. He completed his BA in Medicine from Guangzhou Medical College, Guangzhou, P.R. China (1985). Dr. Xu zeng did his Residency in Pathology from North Shore Uni-Long Island Jewish Medical centre, New Hyde Park, New York (2000-2004). He did his Fellowship in Renal Pathology from the Johns Hopkins Medical Institute Baltimore, Maryland (2004-2005). He served as a Director in Nephrolopathology, Department of Pathology in Wayne State University School of Medicine (2005-2012).

Dr. Xu zeng’s research interests include Renal pathology in kidney disease and transplantation

PubMed

Dr. C. Cameron Yin is an associate professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center and UT Graduate School of Biomedical Sciences. She has received her MD from Beijing Medical University and her PhD from the University of Wisconsin-Madison. Dr. C. Cameron Yin is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, Hematology and Molecular Genetic Pathology. In addition to clinical responsibilities on the Leukemia, Lymphoma and Molecular Diagnostic Laboratory services. Dr. Yin has been actively participating in multiple research projects in leukemia and lymphoma, which has led to over 100 research papers and over 20 book chapters. She serves as member of editorial boards for over 20 journals and ad hoc reviewers for over 30 journals.

Dr. C. Cameron Yin major research interests include molecular genetic aberrations in leukemia and lymphoma, development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms, mechanisms of resistance to tyrosine kinase inhibitors in patients with chronic myelogenous leukemia, as well as the role of immunoglobulin gene rearrangement in acute myeloid leukemia.

PubMed

Dr. Weibiao Cao is an associate professor in the Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI. He received MD from Zhejiang Medical University, Hangzhou, China in 1986. From 1986 to 1995 he worked as a resident, chief resident and attending physician in the Department of Medicine, Peking Union Medical College Hospital, Beijing China. In 1995 he was hired as a Postdoctoral research assistant at the University of Calgary, Canada. In February, 1996, Dr. Cao joined Gastrointestinal Motility Research Lab, Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University. Dr. Cao has been an attending pathologist in Department of Pathology and Medicine at RI hospital. He has published 62 original research articles, two book chapters and 95 abstracts.

Dr. Weibiao Cao research interest is focused on signal transduction pathway in esophageal and lower esophageal sphincter circular muscle and the contractile signal transduction in ulcerative colitis, the role of NADPH oxidases, in particular NOX5, in the progression from Barrett’s esophagus to esophageal adenocarcinoma.

PubMed

Dr. Dengfeng Cao is currently an associate professor of pathology and immunology in Washington University School of Medicine in Saint Louis, USA. Dr. Cao obtained his M.D. from Peking Union Medical College in Beijing in 1996 and Ph.D. from University of Pittsburgh in 2002. He finished his residency training in anatomic and clinical pathology and subsequent advanced subspecialty training in surgical & gynecologic pathology in the Johns Hopkins Hospital between 2001 and 2007. Dr. Cao practices surgical pathology with diagnostic expertise in gynecologic pathology, genitourinary pathology and pancreatic pathology. He has contributed two WHO blue books (WHO Classification of Tumors of Female Genital Organs, 4th edition, 2014; WHO Classification of Tumors of Urinary System and Male Genital Organs, 4th edition, 2016). Dr. Cao has published more than 60 peer-reviewed research papers and is currently an editorial board member of several pathology journals.

Dr. Dengfeng Cao research Interest includes Morphologic analysis, diagnostic and prognostic biomarkers in gynecologic pathology, genitourinary pathology and pancreatic pathology.

PubMed

Dr. Lina Shao is an Associate Professor in Department of Pathology at the University of Michigan, Ann Arbor. She received both MD and PhD from Zhejiang University, China. Dr. Shao completed postdoctoral training in Epidemiology at the University of Texas MD Anderson Cancer Center and ABMG fellowship in Clinical Cytogenetics at Baylor College of Medicine. She was awarded a development grant from The University of Texas SPORE in Lung Cancer. Dr. Shao joined faculty at the University of Michigan in 2009 and now serves as the Director of Clinical Cytogenetics Laboratory. She is board certified in Clinical Cytogenetics and is a fellow of American College of Medical Genetics (FACMG). Dr. Shao is also an active member of American College of Medical Genetics, Association for Molecular Pathology and Cancer Cytogenomic Microarray Consortium.

Dr. Shao’s current research interest includes cytogenetics of constitutional and neoplastic disorders, whole genome SNP array application in diagnosis and prognosis of hematological malignancies and pediatric solid tumors.

PubMed

Dr. Prabir Kumar Chakraborty is an assistant professor of Oklahoma University health science center in the field of Role of CBS in Ovarian Cancer at Oklahoma university of Oklahoma City at Oklahoma. He is a Member of the advisory committee for research work in oncology at Barasat Cancer Research and Welfare Centre, Kolkata (India). He was awarded a full time Research Fellowship (2002-2008) by Saha Institute of Nuclear Physics, an autonomous organization under Department of Atomic Energy, Govt. of India after completion of Post M.Sc. Associateship course in Biophysical Sciences.

Dr. Prabir Kumar Chakraborty’s research interests are Cancer cell biology, cell signaling, cancer biomarkers, cell migration , metastasis, post translational modifications of proteins, GPCRs and heat shock proteins.

PubMed

Dr. Noah Brown is an Assistant Professor in the Department of Pathology at the University of Michigan. He received a B.S. in Biological Sciences from Stanford University and an M.D. from the University of Michigan School of Medicine. He completed residency training in Anatomic and Clinical Pathology at the University of Michigan Health System. He also completed fellowships in Hematopathology and in Molecular and Genetic Pathology at the University of Michigan. He joined the faculty at the University of Michigan, Department of Pathology in 2014 and is now the Medical Director of the University of Michigan Molecular Diagnostics Laboratory. Recent achievements include the 2014 Association for Molecular Pathology Young Investigator Award.

Dr. Brown’s research interests include molecular pathogenesis of head and neck and hematolymphoid neoplasms. Recent work has included the role of MAPK pathway mutations in ameloblastoma, MAP2K1 mutations in Langerhans cell histiocytosis and EGFR mutations in sinonasal papillomas and squamous cell carcinomas.

PubMed

Dr. Octavia M. Peck Palmer is a board certified (National Registry of Clinical Chemists) Clinical Chemist and an Assistant Professor at the University of Pittsburgh School of Medicine with a primary appointment in the Department of Pathology and secondary appointments in the Departments of Critical Care Medicine and Clinical & Translational Science. She also serve as the Medical Director of the Automated Testing Laboratories (includes general/immunochemistry, therapeutic drug monitoring, blood gas and urinalysis testing) at the University of Pittsburgh Medical Center hospitals (Presbyterian, Shadyside, Magee-Women’s Hospital, and Children’s Hospital of Pittsburgh). She has authored >20 publications that span the fields of pathology, clinical chemistry, physiology, and immunology.

Dr. Peck Palmer’s research focuses on understanding the signaling mechanisms that mediate differential host immune responses to infection across racial groups and the differences that are associated with susceptibility to infection and risk of death. Severe sepsis is the 10th leading cause of death and Black Americans have a higher incidence of severe sepsis compared to white and Hispanic Americans. Dr. Palmer examines the peripheral blood mononuclear gene expression changes associated with adverse outcomes in sepsis, the distribution of zinc single nucleotide polymorphisms (SNPs) across racial groups, the association of the SNPs with susceptibility to infection, risk of severe sepsis and mortality and the functional consequence of the SNPs on inflammatory mediator production, hemostasis and apoptosis. Delineation of specific biological differences will have a key impact on current treatments and development of target therapies for both community-acquired pneumonia and severe sepsis.

PubMed

Dr. Qing (Grace) Zhao is a currently an Assistant Professor at Boston University School of Medicine (BUSM) in the Department of Pathology and Laboratory Medicine. She received her M.D. from Norman Bethune University of Medical Science (now called Jinlin University) in Changchun China and continued with her Master of Science Degree in basic medical science majored in molecular biology and biochemistry at the same University. After graduation, she moved to a new developing urban city (Shenzhen) and worked for a biotech company for one year. In 1994, she was accepted as a PhD student in McGill University with a full scholarship, and obtained her PhD degree in 2000. She had then accomplished her postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School in 2006. In the fall of 2006, she was successfully matched into AP/CP pathology program at University of Texas Medical Branch and accomplished her residency training. She continued with one year surgical pathology fellowship followed by one year GI and Liver Subspecialty Fellowship trainings in the Department of Pathology at MD Anderson Cancer Center in 2012.

Dr. Qing (Grace) Zhao’s research interests are molecular biology and tumorigenesis of colorectal and pancreatic cancers. Dr. Zhao is also interested in understanding the developmental associated transcriptional factors in tumoriogenesis.

PubMed

Dr. Xuchen Zhang, is an Assistant Professor of Pathology at Department of Pathology of VA Connecticut Health System & Yale University School of Medicine, who is board-certified in anatomic/clinical pathology. He has clinical interests in liver/GI pathology, head and neck pathology, and neoplastic and non-neoplastic pulmonary pathology. He completed his medical degree at Chengde Medical College, his master’s at Beijing University of Chinese Medicine and his doctorate at Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang conducted research as Post-doc and Associate Research Scientist at Yale University School of Medicine from 2000 to 2007 in the field of acute and chronic oxidant-induced lung injury. In addition, he completed his pathology residency at State University of New York at Downstate Medical Center, and Liver/GI pathology fellowship at Mount Sinai School of Medicine. He is serving as reviewer and editorial board member for several journals, and has more than 70 publications.

Dr. Xuchen Zhang’s research interests are drug-induced hepatotoxicity and gastrointestinal injury, molecular pathogenesis of colon cancer and hepatocellular carcinoma, acute and chronic oxidant-induced lung injury and underlying molecular mechanisms.

PubMed

Dr. Jiaqi Shi is an Assistant Professor in the Department of Pathology, University of Michigan, USA. She received her MD and PhD from Hunan Medical University (now Xiang Ya Medical School, Central South University), China in 1995 and 1999 respectively. From 1999 through 2010, Dr. Shi served as a Postdoctoral Fellow and later Assistant Professor at the University of Arizona with an NIH-funded research focus on pancreatic cancer. Dr. Shi completed her residency in anatomic and clinical pathology at the Department of Pathology, University of Michigan in 2014. Among her many awards, Dr. Shi has won the 2011 Benjamin Castleman Award from the United States and Canadian Academy of Pathology (USCAP). She is currently active members of the USCAP, ASCP, CAP, Rodger C. Haggitt Gastrointestinal Pathology Society, Hans Popper Hepatopathology Society, and the Michigan Society of Pathologists.

Dr. Jiaqi Shi research interests are pancreas pathology, integrative clinical sequencing, metabolic profiling, and proteomics for personalized medicine in pancreatic neoplasms; Signalling pathways contribute to the tumorigenesis and development of pancreatic neoplasms; Discovery of new biomarkers for early diagnosis, prognosis and therapeutic targets of pancreatic cancers.

PubMed

Dr. Nicoleta C Arva is an Assistant Professor of Pathology at Feinberg School of Medicine, Northwestern University and pediatric pathologist at Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL. She received her medical degree from “Gr. T. Popa” University of Medicine in Iasi, Romania and her PhD degree in Molecular Biology from City University of New York. The research focus of her doctoral studies was Mdm2 oncoprotein. She was trained in pathology as resident at University of Illinois at Chicago, followed by fellowships in general surgical pathology at New York University and in pediatric pathology at Children’s Hospital of Philadelphia, University of Pennsylvania. Dr. Nicoleta C Arva received many honours and awards. She has published many research papers. She is actively involved in clinical teaching of residents/fellows while rotating in pediatric pathology.

Dr. Nicoleta C Arva research interests is in pediatric gastro-intestinal diseases as well as in pediatric medical kidney. Eosinophilic gastro-intestinal diseases, pediatric thyroid neoplasms, molecular pathways in pediatric soft tissue tumors.

PubMed

Dr. Sonika Dahiya is currently an Assistant Professor in Department of Pathology & Immunology at Washington University School of Medicine in St. Louis. She completed her medical schooling and Pathology residency in India followed by a research fellowship in Molecular Pathology (Massachusetts General Hospital and Harvard Medical School), retraining in Pathology (New York University School of Medicine) and Neuropathology fellowship (Washington University School of Medicine) in USA. 

Dr. Sonika Dahiya's research focuses on discovery of novel diagnostic, prognostic and predictive markers in brain tumors.

PubMed

Dr. Priyadharsini Nagarajan is a Dermatopathologist and physician scientist currently working as an Assistant Professor at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She earned her PhD in Biomedical Sciences from the University of Buffalo (2008). She did her medical training in India, and residency in Anatomic and Clinical Pathology at Yale School of Medicine (2008-2012). Her Dermatopathology fellowship training was at the Ohio State University. She has received many honours and awards. Dr. Priyadharsini has published 5 book chapters and many research articles.

Dr. Priyadharsini Nagarajan research interest is in Dermatopathology . However, her primary focus of research is the study of etiopathogenesis, prevention and treatment of cutaneous squamous cell carcinomas, using cell culture and mouse models as well as by examination of archived human tissues, particularly in elucidating the molecular mechanisms that contribute to aggressive behavior of squamous cell carcinomas in the setting of immunosuppression. Her other interests include melanomas of the vulva, alopecia and infectious diseases of skin.

PubMed